Contact
Please use this form to send email to PR contact of this press release:
Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID
TO: